COVID-19 outpatient thrombosis prevention trial ends early

A year ago, investigators set out to study whether symptomatic COVID-19 outpatients should be given anticoagulant or antiplatelet therapy to prevent clots that were reported among some patients with COVID-19. The data collected to date, through a randomized, double-blinded, placebo-controlled trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI), suggests a very low rate of thrombotic complications in the patients studied. Trial leadership has found that for mildly symptomatic COVID-19 outpatients who have been sick at home for at least a week and who remain clinically stable and have no risk factors for thrombotic events, rates of major cardio-pulmonary complications do not justify antithrombotic therapy. Given these data, the study’s Data and Safety Monitoring Board has recommended to end the trial.


Share on facebook
Share on twitter
Share on pinterest
Share on linkedin

Leave a Reply

Related Posts

Vitamins and Minerals

Vitamins and minerals are micronutrients required by the body to carry out a range of normal functions. However, these micronutrients are not produced in our